

1 **Rigorous hepatitis B surface antigen analyses and identification of hepatitis B chronicity amongst South**
2 **Africans attending public health facilities over a five-year period: 2015 to 2019**

3 Shelina Moonsamy^{1,2*}, Pavitra Pillay², Nishi Prabdial-Sing^{1,3}

4 ¹Centre for Vaccines and Immunology, National Institute for Communicable Diseases, division of the National
5 Health Laboratory Service, Johannesburg, South Africa

6 ²Department of Biomedical and Clinical Technology, Faculty of Health Sciences, Durban University of
7 Technology, Durban, South Africa

8 ³Department of Medical Virology, School of Pathology, Faculty of Health Sciences, University of the
9 Witwatersrand, Johannesburg, South Africa

10
11 * Corresponding author

12 E-mail: shelinam@nicd.ac.za

27 **Abstract**

28 Hepatitis B, a potentially life-threatening viral infection of the liver, remains a global public health concern despite the
29 availability of effective vaccines for over three decades. Given that most HBsAg studies targeted distinct cohorts, we
30 aimed to provide HBsAg data nationally in the public health sector of South Africa.

31 We conducted a cross-sectional study on HBsAg tests obtained from the National Health Laboratory Service Central
32 Data Warehouse for tests performed nationally during the period 2015 to 2019. Annual data were cleaned and appended
33 prior to data interrogation to determine and analyse the total number of cases who tested positive for HBsAg and the
34 number of chronic HBV infections.

35 We identified 176,530 cases who tested positive for HBsAg at least once during the 5-year period, with a test positivity
36 rate of 9%. Chronic infections were identified in 6.4% of HBsAg positive cases. Clearance of HBsAg was observed in
37 5,571 cases, inclusive of clearance in 135 chronic cases. Significantly more males tested positive for HBsAg and were
38 chronically infected ($p < 0.0001$). Amongst individuals who were vaccine-eligible as infants (0 to 19 years old), 4,980
39 tested HBsAg positive, of which 22.7% (1,131) were under 5 years old, with a HBsAg population positivity rate of 0.02%
40 and test positivity rate of 4.83%.

41 HBsAg positivity amongst vaccine-eligible individuals is likely due to suboptimal vaccine coverage rates reported for
42 South Africa. Without a birth dose of the HBV vaccine and lack of routine HBsAg screening at antenatal care, it is likely
43 that the majority of HBsAg positive cases under 5 years old were vertically infected. Optimal HBV vaccine coverage,
44 inclusive of a birth dose, is key to eliminating horizontal and vertical transmission of HBV. Early identification of HBV
45 chronicity is fundamental in reducing the risk of liver cirrhosis and hepatocellular carcinoma.

46

47

48

49

50

51

52

1. Background

53 Hepatitis B, a potentially life-threatening viral infection of the liver, remains a global public health concern despite the
54 availability of effective vaccines for over three decades (1-3). It occurs following infection with the hepatitis B virus (HBV).
55 HBV is transmitted through contact with blood or other body fluids of an infected person. Common transmission routes
56 are sexual contact, intravenous drug use and vertical transmission from mother to child during birth (4). Infection with
57 HBV can cause acute and chronic disease. The risk of progression to chronicity decreases with age, ranging from around
58 70-90% amongst infants less than a year old to 1-10% amongst individuals over 20 years old (5-7). Resolved HBV
59 infection usually results in hepatitis B immunity that prevents disease following re-exposure, however HBV reactivation
60 or reinfection, as identified by the reappearance of detectable HBsAg levels, has been reported in individuals infected
61 with HIV-1 (8). Chronically infected individuals have a 15-40% lifetime risk of cirrhosis, liver failure or hepatocellular
62 carcinoma and although chronic HBV infection has no known cure, disease progression can be managed with various
63 treatment options as highlighted in the National Guidelines for the Management of Viral Hepatitis (9-11). In 2019, The
64 World Health Organisation (WHO) estimated that 296 million people were living with chronic HBV infection, a 15%
65 increase from the 2017 estimate of 257 million (12, 13). In June 2016, the World Health Assembly adopted a resolution
66 to eliminate viral hepatitis as a major public health problem by 2030 (1). Elimination is targeted at reducing new chronic
67 infections by 90% and HBV related deaths by 65% (1). In addition, one of the WHO impact targets for measuring
68 elimination is $\leq 0.1\%$ HBsAg prevalence in children under 5 years old (14).

69 HBV infection is diagnosed following laboratory detection of HBsAg, which indicates active infection (15). If HBsAg is
70 not cleared within six months of first detection, HBV infection is classified as chronic (1, 16, 17). HBsAg clearance
71 amongst chronically infected HBV individuals may occur in around 1-2% of individuals, either naturally or following
72 treatment interventions (18, 19).

73 Hepatitis B was highly endemic in South Africa before April 1995 when the HBV vaccine was introduced as a monovalent
74 dose into the South African expanded programme on immunisation (EPI) schedule (20). Since December 2015, the HBV
75 vaccine is one of the vaccines amongst the hexavalent combination vaccine of diphtheria, tetanus, acellular pertussis,
76 inactivated poliovirus, Haemophilus influenza type B and hepatitis B (DTaP-IPV-HIB-HepB). The current HBV
77 vaccination schedule consists of doses at 6, 10 and 14 weeks of age, and a booster dose at 18 months of age (21, 22).
78 Although recommended to minimise the risk of mother to child transmission of HBV, a birth dose of the HBV vaccine is
79 yet to be included in the EPI schedule of South Africa (23, 24). Vaccination coverage for South Africa amongst children

80 under one year old who have completed their primary course of immunisation has been reported from 2000 to 2019 by
 81 the Health Systems Trust of South Africa using data obtained from the District Health Information System (25-29). Over
 82 the 20-year period, the average coverage rates by province ranged from 67.2% in North West to 85.6% in Northern
 83 Cape (S1 Table).

84 In South Africa, chronic HBV prevalence has been estimated at 2.5 million cases, reported in 2014 (6). Based on the
 85 population size of South Africa in 2014 at just over 54 million, this would translate to a HBsAg prevalence of 4.6%,
 86 indicative of intermediate HBV endemicity (2 to 7% HBsAg prevalence) (20, 30-32). A major transmission route in South
 87 Africa was reported to be unexplainable horizontal transmission in children under 5 years of age, whilst sexual
 88 transmission was reported to be the major transmission route amongst adolescents and young adults (20).

89 Over the five years, 2015 to 2019, the average population of South Africa, as reported by Statistics South Africa was
 90 just under 57 million (Table 1) (33). Overall, there were higher numbers of females than males, although in Gauteng and
 91 North West, there were slightly more males than females. Provincially, the smallest province of South Africa (Gauteng),
 92 housed the majority of South Africans, whilst the largest province (Northern Cape, just over 20-fold larger) housed the
 93 least number of South Africans at more than 10-fold lower than Gauteng (Table 1).

94 **Table 1: Land size versus population size by province of South Africa**

Province	Land size		Population size	
	Area (km ²) (34)	Percentage	Number* (33)	Percentage
Northern Cape	372,889	30.5	1,241,454	2.2
Eastern Cape	168,966	13.8	6,663,741	11.7
Free State	129,825	10.6	2,865,681	5.0
Western Cape	129,462	10.6	6,608,058	11.6
Limpopo	125,755	10.3	5,719,236	10.1
North West	104,882	8.7	3,893,193	6.8
KwaZulu-Natal	94,361	7.7	11,011,040	19.4
Mpumalanga	76,495	6.3	4,424,866	7.8
Gauteng	18,178	1.4	14,426,736	25.4
Total	1,220,813	100	56,854,006	100

95 *The population size indicated here is the average population size from 2015 to 2019

96 Most HBsAg studies that have been conducted in South Africa targeted distinct cohorts (20, 22, 23, 35-40). Hence, the
 97 aim of the study was to describe and analyse the number of cases that tested positive, at least once, for HBsAg in a
 98 consecutive five-year period and to identify and analyse HBV chronic cases nationally in the public health sector of
 99 South Africa.

2. Methods

2.1 Study Population and Data Source

We conducted a cross-sectional study on HBsAg tests obtained from the National Health Laboratory Service (NHLS) Central Data Warehouse (CDW) for tests performed nationally during the period 2015 to 2019. The NHLS CDW is the national repository for laboratory data from the public health sector of South Africa, serving over 80% of the population (41). Variables of the dataset used for the purposes of this study were gender, date of birth (DOB), province (assigned to the testing facility), date of sample collection, name of testing facility, testing facility reference number (hospital identification number) and a CDW allocated unique identification number (UID). The UID is duplicated if a link to an existing record is identified based on the surname, first name and date of birth or national identification number, otherwise a new UID is generated. Criteria for inclusion in our study were negative and positive HBsAg results.

2.2 Data Cleaning and Appending

Data were initially cleaned per year from 2015 to 2019 in Microsoft Excel (Version 2016, Washington, USA) by identification, confirmation and deletion of quality assurance (non-patient related) records. Annual data were subsequently cleaned following importation into Stata/IC (Version 14.1, Texas, USA) to remove records of research study participants and format date variables according to the “DD/MM/YYYY” format prior to saving as Stata (.dta) files. Annual .dta files were appended into a single dataset containing all HBsAg test records from 2015 to 2019, sorted by the sample collection date and saved for further data manipulation.

2.3 Data Analyses

Data analyses were performed in in Stata/IC (Version 14.1, Texas, USA) and Microsoft Excel (Version 16, USA).

To determine the total number of cases who were tested for HBsAg over the five years, we de-duplicated the appended 2015 to 2019 dataset to obtain a line list of cases and used this as our denominator for HBsAg prevalence (%). To obtain a dataset of all HBsAg positive and negative records, we used the original appended dataset to identify and delete HBsAg records of equivocal results (neither positive nor negative) and sorted the dataset by the sample collection date (herein referred to as the master HBsAg dataset). We proceeded to identify cases that had only a single HBsAg test and

125 cases with multiple HBsAg tests during 2015 to 2019. For those cases with more than one test, we merged the dataset
126 so that a case would appear as a single line item with the variables of HBsAg test results and sample collection dates
127 merged to include all results and sample collection dates of a specific case respectively. We then analysed the merged
128 dataset over the five-year period to identify cases who tested negative throughout (Group_N), cases who tested positive
129 throughout (Group_P), and cases who had mixed results of both negative and positive (Group_M). Group M was further
130 interrogated to identify the number of cases that (1) tested negative after testing positive, (2) tested positive after an
131 initial negative result and (3) tested negative in between two positive results.

132 **2.3.1 Development of a registry of cases who tested positive for HBsAg, 2015** 133 **to 2019**

134 To identify cases that tested positive at least once over the 5 years, we selected all HBsAg positive records (comprising
135 cases from Group_M and_Group P) and maintained a dataset of these records (herein referred to as the positive HBsAg
136 positive dataset). As a registry requires a line list of cases, we de-duplicated the positive HBsAg dataset to delete all
137 duplicate records of a case over the 5-year period to maintain a line list (registry) of cases.

138 **2.3.2 Identification of chronic HBV cases**

139 We used the positive HBsAg dataset to identify and delete cases who had only one positive test over the five years,
140 maintaining records of all cases who had more than one HBsAg positive test. We then merged the records to have each
141 case appear as a single line item inclusive of all sample collection dates in ascending chronological order. We calculated
142 the time interval in days between the first sample collection date and subsequent sample collection dates and maintained
143 only records of cases who met the criteria of a time interval of 180 days (6 months) or more and classified them as
144 chronic HBV cases (Group_C).

145 We subsequently determined how many chronic HBV cases were from Group_P and the different categories of Group_M
146 by merging the Group_C .dta file with Group_P and the different categories of Group_M .dta files using the UID as the
147 key variable.

148 **2.3.3 Age group analysis**

149 We calculated the age of each case based on the sample collection date and date of birth and subsequently assigned
150 the cases to defined five-year age groups. With the master HBsAg dataset sorted by the sample collection date, age

151 groups presented are based on the earliest sample collection date if a case had more than one record. We analysed
152 age group 0 to 4 years old further to determine HBsAg test positivity rate (HBsAg positive cases / total cases 0 to 4
153 years old tested for HBsAg) and HBsAg population positivity rate (HBsAg positive cases / average population size 0 to
154 4 years old 2015 to 2019).

155 **2.3.4 Statistical Analyses**

156 We analysed the data to determine the distribution of cases by age group and province stratified by gender, and to
157 determine the number of HBsAg positive cases and HBV chronic cases per 100,000 province population. We used the
158 average population over the five years (2015 to 2019) as reported by Statistics South Africa (33). To analyse statistical
159 differences between gender by age group, we used Pearson's chi-squared test in Stata/IC (Version 14.1, Texas, USA).

160 **2.3.5 Ethics**

161 Ethics approval was obtained from the Faculty of Health Sciences, Institutional Research Ethics Committee (IREC
162 069/20) of the Durban University of Technology, Durban, South Africa. Approval to obtain the NHLS CDW data was
163 obtained via the NHLS Academic Affairs and Research Management System (PR20254).

164 **3. Results**

165 Following data cleaning and appending of annual HBV data files, the appended 2015 to 2019 HBsAg dataset consisted
166 of a total of 2,370,723 records (42). Deduplication of the dataset resulted in a line list of 1,957,224 cases (denominator
167 for HBsAg prevalence) who were tested for HBsAg over the five years (Fig 1a). Of the 2,370,723 records, 6,211 records
168 with equivocal results and were deleted, leaving 2,364,512 records of positive and negative HBsAg results (master
169 HBsAg dataset) (Fig 1a). Of the master HBsAg dataset, 1,655,484 cases had only one HBsAg test conducted from 2015
170 to 2019 (Fig 1b). The remaining (709,028) were from cases who were tested for HBsAg at least twice during the five-
171 year period. On merging the duplicates of the dataset of 709,028 records, we identified 297,267 cases with duplicate
172 records; 252,429 cases in Group_N, 8,645 cases in Group_M and 36,193 cases in Group_P (Fig 1b). Of the 8,645 cases
173 in Group_M, 5,571 cases tested negative after a positive test, 3,001 cases tested positive after a negative test, and 73
174 cases tested negative in between an initial and last positive test (Fig 1b). Of the 5,571 cases who tested negative after
175 a positive test, 4,907 cases had tested positive initially and negative subsequently and 664 cases tested positive in
176 between an initial and last negative test (Fig 1b).

177 **Figure 1: HBsAg sample number breakdown from the appended dataset of records from 2015 to 2019; from the**
178 **dataset of valid HBsAg results to the master HBsAg dataset (a), from the master HBsAg dataset to a breakdown**
179 **of Group_M (b), and from the master HBsAg dataset to a breakdown of Group_C (c)**

180 **3.1 Registry of cases who tested positive for HBsAg, 2015 to**

181 **2019**

182 From the master HBsAg dataset of 2,364,512 records of positive and negative HBsAg tests, we identified and extracted
183 232,551 records of positive HBsAg results (positive HBsAg dataset) (Fig 1c). Deduplication of cases resulted in a line
184 list (registry) of 176,530 cases who had tested positive for HBsAg at least once during the five-year period, with a test
185 positivity rate of 9.0% (176,530 / 1,957,224) (Fig 1c).

186 **3.1.1 Analyses of the 2015 to 2019 HBsAg registry**

187 Of the 176,530 HBsAg positive cases, significantly more males (94,698, 53.6%) tested positive than females (78,934,
188 44.7%, $p < 0.0001$) (Fig 2a and S2 Table). Individuals aged 25 to 44 years old had the highest proportion of HBsAg
189 positive tests (115,906, 65.7%) (Fig 2b and S2 Table). Individuals 45 years and older accounted for 21.1% of the total
190 HBsAg positive cases (37,200/176,530). The number of HBsAg positive cases 0 to 19 years old (4,980) was significantly
191 lower than the number of HBsAg positive cases 20 years and older (166,259, $p < 0.0001$) (S2 Table). Amongst the 4,980
192 HBsAg positive cases 0 to 19 years old, 1,131 (22.7%) were under 5 years old (S2 Table). In the under 5-year age
193 group, the HBsAg test positivity rate was 4.8%, and the HBsAg population positivity rate was 0.02% (Table 2).

194 **Table 2: HBsAg test positivity and population positivity rate from 2015 to 2019**

Age group 0 to 4 years old	
Number of HBsAg positive cases	1,131
Number of cases tested for HBsAg	23,395
HBsAg test positivity rate (%)	4.83
Average population size 2015 to 2019	5,679,585
HBsAg population positivity rate (%)	0.02

195
196 At a provincial level, of the 176,530 HBsAg positive cases, Gauteng had the highest proportion of cases
197 (65,085/176,530, 36.9%), followed by Kwazulu-Natal (35,532, 20.1%) and Eastern Cape (21,280, 12.1%), with the

198 lowest proportion in the Northern Cape (1,827, 1.0%) (Fig 2c and S2 Table). Stratified by gender, the number of HBsAg
199 positive males were significantly higher than females in eight of the nine provinces ($p \leq 0.0306$), except in Limpopo with
200 a significantly higher proportion in females ($p = 0.0103$) (S2 Table). The number of HBsAg positive cases per 100,000
201 population was highest in Gauteng (450/100,000), comparable between Kwazulu-Natal (322/100,000), Eastern Cape
202 (318/100,000) and Mpumalanga (319/100,000), and least in Northern Cape (148/100,000) (Fig 2c).

203 **Figure 2: National distribution of HBsAg positive cases 2015 to 2019 (n = 176,530); province by gender (a) age**
204 **group by gender (b), and province distribution versus 100,000 province population (c)**

205 **3.2 Chronic HBV cases, 2015 to 2019**

206 Of the positive HBsAg dataset of 232,551 records, we identified 138,101 cases who had only a single positive test
207 over the 5-year period and 94,450 records of cases who had at least two positive HBsAg tests (Fig 1c). Of the
208 138,101 cases who had only a single positive test, 131,692 cases were tested once only over the five years and
209 6,409 cases were tested more than once but with only one positive test. On deleting the 138,101 cases and merging
210 the duplicates of the 94,450 records, we remained with 38,429 cases with at least two positive HBsAg tests. Of the
211 38,429 cases, we identified 11,355 cases who had two positive tests with sample collection dates 180 days or more
212 apart and classified them as HBV chronic cases, assigning them to Group_C (Fig 1c). Of the HBV chronic cases,
213 11,055 cases were from Group_P and 300 cases from Group_M (Fig 1b). Of the 300 cases in Group_M, 130 cases
214 had an initial positive and last negative HBsAg test, 110 cases had an initial negative and last positive HBsAg test,
215 55 cases tested HBsAg negative in-between an initial and last positive HBsAg test, and 5 cases tested HBsAg
216 positive in-between an initial and last negative HBsAg test (Fig 1b). One hundred and thirty five (135) cases tested
217 HBsAg negative after being classified as chronic, whilst the majority (11,220) remained HBsAg positive (Fig 1c).

218 **3.2.1 Analyses of the chronic HBV cases, 2015 to 2019**

219 Amongst the total HBsAg positive cases identified during the five-year period, 6.4% (11,355/176,530) were
220 chronically infected. Analysis of the 11,355 HBV chronic cases showed a significantly higher proportion amongst
221 males (6,211, 54.7%) than females (5,027, 44.3%, $p < 0.0001$), although at ages 15 to 29 years, significantly more
222 females (1588, 62.8%) were identified as chronic carriers than males (941, 37%, p value < 0.0001) (Fig 3a and S3
223 Table). The majority of the cases were amongst the ages of 25 to 49 years (9,230, 81.3%) (Fig 3b and S3 Table).

224 Provincially, the majority of the chronic cases were from Gauteng (3,811, 33.6%), followed by Kwazulu-Natal (2,398,
225 21.1%) and Eastern Cape (2,198, 19.4%), with the least number of cases in Northern Cape (89, 0.8%) (Fig 3c and
226 S3 Table). HBV chronic cases per 100,000 province population was highest in Eastern Cape (33/100,000), followed
227 by Gauteng (26/100,000) and Kwazulu-Natal (22/100,000), and least in Limpopo (4/100,000) (Fig 3c). Stratified by
228 gender, the number of HBV chronic males were higher than females in all provinces except Eastern cape,
229 significantly higher in Free State, Gauteng, Kwazulu-Natal, Mpumalanga, North West and Western Cape ($p \leq$
230 0.0254) (Fig 3c and S3 Table). In Eastern Cape, although more females were chronically infected than males, the
231 difference was not significant ($p = 0.1202$) (Fig 3a and S3 Table).

232 **Figure 3: National distribution of HBV chronic cases 2015 to 2019 (n = 11,355); province by gender (a), age**
233 **group by gender (b), and province distribution versus 100,000 province population (c)**

234 4. Summary and Discussion

235 We analysed countrywide HBsAg laboratory data from 2015 to 2019 to determine the number of cases who tested
236 positive for HBsAg and the number of cases with chronic HBV infection. Over the five years, the HBsAg test positivity
237 rate was 9.0%, of which 6.4% were identified as chronic carriers. We noted that the majority of the HBsAg positive cases
238 and HBV chronic cases were amongst cases who were born pre 1995, outside the vaccine-eligible era and therefore
239 foreseeable. Numbers of HBsAg positive cases were much lower amongst individuals who were vaccine-eligible as
240 infants (0 to 19 years), demonstrating effective vaccination in these groups. As vaccination is key to prevention of HBV
241 infection, HBsAg positivity amongst vaccine-eligible individuals is likely due to the suboptimal vaccine coverage rates
242 reported for South Africa from 2000 to 2019 (25-29). Suboptimal vaccine coverage rates may have largely been due to
243 the challenges that faced EPI activities in South Africa, highlighted by EPI managers as being insufficient knowledge of
244 vaccines and EPI practices among staff, financial constraints, staff shortages and high staff turn-over (43).

245 More males were HBsAg positive and chronically infected overall, although more females were HBsAg positive at ages
246 10 to 29 years and chronically infected at ages 15 to 29 years. The higher rate amongst males overall is compounded
247 by the fact that the average population size over the five years was higher in females. The higher rates observed in
248 females 10 to 29 years old are likely due to their increased risk of symptomatic infection following viral infections, coupled
249 with higher health seeking tendency including antenatal visits at these ages (44). The higher rates in males overall and
250 at later ages are likely due to the increased risk of persistent HBV infection in males resulting in their increased risk of

251 HBV chronicity (45, 46). This is in keeping with studies conducted in Taiwan, Greece and New Zealand, where it was
252 reported that females were less likely to develop chronic HBV infection than males (46-48). In a study on sex differences
253 in response to HBV infection, Blumberg reports that the prevalence of chronic carriers amongst males is higher than
254 females in most human populations (49). In children 0 to 4 years old, we noted a sizeable number of HBsAg positive
255 cases from 2015 to 2019 (1,131). With no birth dose of the HBV vaccine administered to these children and no routine
256 screening for HBsAg at antenatal care, we suspect a considerable proportion were infected from their mothers given the
257 increased risk with no preventative interventions (6, 10, 23, 24). Although horizontal transmission has been reported as
258 a major transmission route between children in South Africa, justifiable reasons are lacking (20, 50). Considering the
259 WHO impact target of $\leq 0.1\%$ HBsAg prevalence for measuring elimination in children under 5 years old and the South
260 African under 5 year HBsAg population positivity rate (population prevalence), South Africa is well below the target over
261 2015 to 2019 at 0.02% (14). However, the data presented are only from children tested in public healthcare facilities and
262 it is likely that a substantial proportion of children under 5 years old were not HBsAg diagnosed given the low risk of
263 symptomatic HBV infection in children (1). Substituting the denominator with the total number of cases under 5 years
264 old who were tested for HBsAg over the five years, the HBsAg test positivity rate (test prevalence) was 4.83%, well
265 above the 0.1% target.

266 Provincially, we noted that the number of HBsAg positive cases and the number of HBV chronic cases were highest in
267 Gauteng, followed by Kwazulu-Natal and Eastern Cape and lowest in the Northern Cape, not surprising given that the
268 average population size of these four provinces from 2015 to 2019 follows the same pattern. In addition, the findings in
269 Gauteng and Northern Cape may also be related to the land size of these provinces versus their population sizes (Table
270 1) (51). Furthermore, Northern Cape boasted the highest average vaccine coverage rate from 2000 to 2019 (85.57%)
271 (S1 Table). Taking into consideration population size per province, Eastern Cape was seen to have the highest number
272 of chronic HBV cases in the country (33/100,000), in keeping with one of the poorest vaccine coverage rates averaging
273 69,54% from 2000 to 2019. Surprisingly, however, there were more chronic infections in females in Eastern Cape,
274 despite significantly higher HBsAg positive tests in males. Regarding gender distribution, we saw that significantly more
275 females tested positive for HBsAg in Limpopo province, yet more males were chronically infected. We link this finding in
276 Limpopo to the increased risk of symptomatic infection following viral infections in females together with the increased
277 risk of persistent HBV infection in males (44-46). Although reasons are unclear, we are cognisant of provincial public
278 health disparities within South Africa and suboptimal vaccine coverage rates (S1 Table) (52). Therefore, provincial

279 investigations, including community awareness, HBV testing and follow up practises, social practises, and vaccination
280 policies would provide insight into provincial HBV burden.

281 From analyses of cases who tested negative and positive for HBsAg over the five years (Group_M), we saw that 64.4%
282 (5,571/8,645) of cases tested negative after a positive test, suggesting HBsAg clearance and resolution of HBV infection.
283 Analyses of testing patterns showed that amongst the cases who tested negative after a positive test, 11.9% (664/5,571)
284 of cases tested negative before testing positive, indicating that in these individuals HBV infection was likely acquired
285 during 2015 to 2019 and likely amongst those individuals who did receive or complete their primary course of
286 vaccinations. We also observed a small proportion (73/8,645, 0.8%) of cases from Group_M who tested HBsAg negative
287 between two positive tests, suggesting HBsAg clearance after acquiring HBV infection followed by reactivation of HBV
288 disease or HBV reinfection, a phenomenon seen amongst HIV-1 infected individuals (8). Amongst the 11,355 chronic
289 HBV cases, we report a last negative HBsAg test over the five years in 1.2% of cases following classification as chronic,
290 in line with reported statistics of HBsAg clearance observed in 1-2% of chronic infections following the natural course of
291 disease or treatment interventions (18, 19).

292 A limitation of this study is that we report findings restricted to passive surveillance over a fixed period of time. Population
293 prevalence rates include South Africa's total population as the denominator and our findings are from individuals
294 attending only public healthcare facilities. Our numbers, therefore, represent minimum estimates. Our findings of
295 provincial differences may represent provincial disparities rather than disease burden. In addition, the province is
296 allocated based on the location of the testing facility and patients may have travelled to facilities in provinces outside
297 their place of residence. HBsAg positivity amongst children 0 to 4 years old may be associated with transient positivity
298 soon after vaccination, although reasons for testing in this age group are unclear. Our data were not linked to HIV status
299 and we therefore cannot report on HBV and HIV co-infection or relate our findings to other studies reporting HBV
300 prevalence and chronicity in HIV-infected individuals. A strength of our study, however, is the interrogation of a robust
301 nationally representative public health dataset comprising over 2,3 million records.

302 **5. Conclusion:**

303 Prevention of HBV infection through infant vaccination, inclusive of a birth dose, is key to eliminating HBV infection.
304 Given that the HBV vaccine is administered as a hexavalent vaccine in South Africa, optimal (3-dose) HBV vaccine
305 coverage would not only reduce HBV burden, but would provide protection from other debilitating vaccine-preventable

306 diseases. Early identification of HBV chronicity is fundamental in reducing the risk of liver cirrhosis and hepatocellular
307 carcinoma through appropriate treatment initiation, and can be achieved through real-time data analysis and
308 dissemination of the relevant information for public health interventions.

309 **Acknowledgements:**

310 We acknowledge the NHLS CDW department for providing the 2015 to 2019 hepatitis B data.

311 **References:**

- 312 1. World Health Organisation. Hepatitis B [Available from: [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/hepatitis-b)
313 [sheets/detail/hepatitis-b](https://www.who.int/news-room/fact-sheets/detail/hepatitis-b).
- 314 2. Meireles LC, Marinho RT, Van Damme P. Three decades of hepatitis B control with vaccination. World J
315 Hepatol. 2015;7(18):2127-32.
- 316 3. Bruce MG, Bruden D, Hurlburt D, Zanis C, Thompson G, Rea L, et al. Antibody Levels and Protection After
317 Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. J Infect Dis. 2016;214(1):16-
318 22.
- 319 4. Kim HY. Statistical notes for clinical researchers: Sample size calculation 2. Comparison of two independent
320 proportions. Restor Dent Endod. 2016;41(2):154-6.
- 321 5. Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination
322 on Disease. Clin Liver Dis. 2016;20(4):607-28.
- 323 6. Spearman CW, Sonderup MW. Preventing hepatitis B and hepatocellular carcinoma in South Africa: The case
324 for a birth-dose vaccine. S Afr Med J. 2014;104(9):610-2.
- 325 7. Liang TJ. Hepatitis B: the virus and disease. Hepatology (Baltimore, Md). 2009;49(5 Suppl):S13-S21.
- 326 8. Waite J, Gilson RJ, Weller IV, Lacey CJ, Hambling MH, Hawkins A, et al. Hepatitis B virus reactivation or
327 reinfection associated with HIV-1 infection. AIDS. 1988;2(6):443-8.
- 328 9. Tang C-M, Yau TO, Yu J. Management of chronic hepatitis B infection: current treatment guidelines, challenges,
329 and new developments. World J Gastroenterol. 2014;20(20):6262-78.

- 330 10. Republic of South Africa NDoH. National Guidelines for the management of viral hepatitis 2019 [Available from:
331 https://sahivsoc.org/Files/SA%20NDOH_Viral%20Hepatitis%20guideilnes%20final_.pdf.
- 332 11. Spearman CW. Towards the elimination of hepatitis B and hepatocellular carcinoma. *S Afr Med J*.
333 2018;108(8b):13-6.
- 334 12. World Health Organisation. Global hepatitis report 2017. 2017.
- 335 13. Easterbrook P, Luhmann N, Newman M, Walsh N, Lesi O, Doherty M. New WHO guidance for country validation
336 of viral hepatitis B and C elimination. *Lancet Gastroenterol Hepatol*. 2021.
- 337 14. World Health Organization. Interim guidance for country validation of viral hepatitis elimination Geneva:
338 World Health Organization; 2021 [13/07/2022]. Available from:
339 [https://www.aidsdatahub.org/sites/default/files/resource/who-interim-guidance-country-validation-viral-hepatitis-](https://www.aidsdatahub.org/sites/default/files/resource/who-interim-guidance-country-validation-viral-hepatitis-elimination-2021.pdf)
340 [elimination-2021.pdf](https://www.aidsdatahub.org/sites/default/files/resource/who-interim-guidance-country-validation-viral-hepatitis-elimination-2021.pdf).
- 341 15. Kraiden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis B virus. *Can J Infect Dis Med Microbiol*.
342 2005;16(2):65-72.
- 343 16. Kwon SY, Lee CH. Epidemiology and prevention of hepatitis B virus infection. *Korean J Hepatol*. 2011;17(2):87-
344 95.
- 345 17. Liang TJ. Hepatitis B: the virus and disease. *Hepatology*. 2009;49(5 Suppl):S13-21.
- 346 18. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. *Antivir Ther*.
347 2010;15(2):133-43.
- 348 19. Liu J, Yang HI, Lee MH, Lu SN, Jen CL, Wang LY, et al. Incidence and determinants of spontaneous hepatitis B
349 surface antigen seroclearance: a community-based follow-up study. *Gastroenterology*. 2010;139(2):474-82.
- 350 20. Burnett RJ, Kramvis A, Dochez C, Meheus A. An update after 16 years of hepatitis B vaccination in South Africa.
351 *Vaccine*. 2012;30 Suppl 3:C45-51.
- 352 21. Dlamini NR, Maja P. The Expanded Programme on Immunisation in South Africa: A story yet to be told. *S Afr*
353 *Med J*. 2016;106(7):675-7.

- 354 22. Prabdial-Sing N, Makhathini L, Smit SB, Manamela MJ, Motaze NV, Cohen C, et al. Hepatitis B sero-prevalence
355 in children under 15 years of age in South Africa using residual samples from community-based febrile rash
356 surveillance. PLoS One. 2019;14(5):e0217415.
- 357 23. Spearman CW, Afihene M, Ally R, Apica B, Awuku Y, Cunha L, et al. Hepatitis B in sub-Saharan Africa: strategies
358 to achieve the 2030 elimination targets. Lancet Gastroenterol Hepatol. 2017;2(12):900-9.
- 359 24. World Health Organisation. Implementation of hepatitis B birth dose vaccination - worldwide, 2016. Wkly
360 Epidemiol Rec. 2018;93(7):61-72.
- 361 25. Massyn N, Day C, Barron P, Haynes R, English R, Padarath A. District Health Barometer 2011/12 Durban: Health
362 Systems Trust; 2013 [Available from:
363 <https://www.hst.org.za/publications/District%20Health%20Barometers/District+Health+Barometer+2011-13.pdf>.
- 364 26. Massyn N, Day C, Dombo M, Barron P, English R, Padarath A. District Health Barometer 2012/13 Durban: Health
365 Systems Trust; 2013 [Available from:
366 <https://www.hst.org.za/publications/District%20Health%20Barometers/Complete%20DHB%202012-2013.pdf>.
- 367 27. Massyn N, Day C, Ndlovu N, Padayachee T. District Health Barometer 2019/20 Durban: Health Systems Trusts;
368 2020 [Available from: [https://www.hst.org.za/publications/District%20Health%20Barometers/DHB%202019-
369 20%20Complete%20Book.pdf](https://www.hst.org.za/publications/District%20Health%20Barometers/DHB%202019-20%20Complete%20Book.pdf).
- 370 28. Massyn N, Day C, Peer N, Padarath A, Barron P, English R. District Health Barometer 2013/14 Durban: Health
371 Systems Trust; 2014 [Available from:
372 https://www.hst.org.za/publications/District%20Health%20Barometers/DHB_2013_14_web.pdf.
- 373 29. Massyn N, Peer N, English R, Padarath A, Barron P, Day C. District Health Barometer 2015/16 Durban: Health
374 Systems Trust; 2016 [Available from:
375 [https://www.hst.org.za/publications/District%20Health%20Barometers/District%20Health%20Barometer%202015_1
376 6.pdf](https://www.hst.org.za/publications/District%20Health%20Barometers/District%20Health%20Barometer%202015_16.pdf).
- 377 30. Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection. Int J Med Sci. 2005;2(1):50-7.

- 378 31. Madihi S, Syed H, Lazar F, Ziyad A, Benani A. A Systematic Review of the Current Hepatitis B Viral Infection and
379 Hepatocellular Carcinoma Situation in Mediterranean Countries. *BioMed Research International*. 2020;2020:7027169.
- 380 32. Zampino R, Boemio A, Sagnelli C, Alessio L, Adinolfi LE, Sagnelli E, et al. Hepatitis B virus burden in developing
381 countries. *World J Gastroenterol*. 2015;21(42):11941-53.
- 382 33. Health SSASADo. Mid-year population estimates 2022 Pretoria: Statistics South Africa; 2022 [updated 28 July
383 202205 August 2022]. Available from: <https://www.statssa.gov.za/publications/P0302/P03022022.pdf>.
- 384 34. Health SSASADo. Stats in brief 2021 Pretoria: Statistics South Africa; 2022 [updated 202105 August 2022].
385 Available from: <https://www.statssa.gov.za/publications/StatsInBrief/StatsInBrief2021.pdf>.
- 386 35. Andersson MI, Maponga TG, Ijaz S, Barnes J, Theron GB, Meredith SA, et al. The epidemiology of hepatitis B
387 virus infection in HIV-infected and HIV-uninfected pregnant women in the Western Cape, South Africa. *Vaccine*.
388 2013;31(47):5579-84.
- 389 36. Ayuk J, Mphahlele J, Bessong P. Hepatitis B virus in HIV-infected patients in northeastern South Africa:
390 prevalence, exposure, protection and response to HAART. *S Afr Med J*. 2013;103(5):330-3.
- 391 37. Boyles TH, Cohen K. The prevalence of hepatitis B infection in a rural South African HIV clinic. *S Afr Med J*.
392 2011;101(7):470-1.
- 393 38. Firnhaber C, Reyneke A, Schulze D, Malope B, Maskew M, MacPhail P, et al. The prevalence of hepatitis B co-
394 infection in a South African urban government HIV clinic. *S Afr Med J*. 2008;98(7):541-4.
- 395 39. Hoffmann CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, Chaisson RE, et al. Hepatitis B virus infection
396 and response to antiretroviral therapy (ART) in a South African ART program. *Clin Infect Dis*. 2008;47(11):1479-85.
- 397 40. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Preimmunization epidemiology of hepatitis B
398 virus infection in South African children. *J Med Virol*. 1999;58(2):111-5.
- 399 41. Ngobeni V, Breitenbach MC, Aye GC. Technical efficiency of provincial public healthcare in South Africa. *Cost*
400 *Effectiveness and Resource Allocation*. 2020;18(1):3.
- 401 42. Moonsamy S, Suchard M, Pillay P, Prabdial-Sing N. Prevalence and incidence rates of laboratory-confirmed
402 hepatitis B infection in South Africa, 2015 to 2019. *BMC Public Health*. 2022;22(1):29.


- 403 43. Wiysonge CS, Ngcobo NJ, Jeena PM, Madhi SA, Schoub BD, Hawkrigde A, et al. Advances in childhood
404 immunisation in South Africa: where to now? Programme managers' views and evidence from systematic reviews.
405 BMC Public Health. 2012;12:578.
- 406 44. Cornell M. Gender inequality: Bad for men's health. South Afr J HIV Med. 2013;14(1):12-4.
- 407 45. Ruggieri A, Gagliardi MC, Anticoli S. Sex-Dependent Outcome of Hepatitis B and C Viruses Infections: Synergy
408 of Sex Hormones and Immune Responses? Front Immunol. 2018;9:2302.
- 409 46. Tsay PK, Tai DI, Chen YM, Yu CP, Wan SY, Shen YJ, et al. Impact of gender, viral transmission and aging in the
410 prevalence of hepatitis B surface antigen. Chang Gung Med J. 2009;32(2):155-64.
- 411 47. Koulentaki M, Spanoudakis S, Kantidaki E, Drandakis P, Tzagarakis N, Biziagos E, et al. Prevalence of hepatitis
412 B and C markers in volunteer blood donors in Crete. A 5-year study. J Viral Hepat. 1999;6(3):243-8.
- 413 48. Robinson T, Bullen C, Humphries W, Hornell J, Moyes C. The New Zealand Hepatitis B Screening Programme:
414 screening coverage and prevalence of chronic hepatitis B infection. N Z Med J. 2005;118(1211):U1345.
- 415 49. Blumberg BS. Sex differences in response to hepatitis B virus. I. History. Arthritis Rheum. 1979;22(11):1261-6.
- 416 50. Kew MC. Hepatitis B virus infection : the burden of disease in South Africa. Southern African Journal of
417 Epidemiology and Infection. 2008;23(1):4-8.
- 418 51. South African Government. South Africa's provinces 2021 [07 October 2021]. Available from:
419 <https://www.gov.za/about-sa/south-africas-provinces>.
- 420 52. Ndwandwe D, Nnaji CA, Wiysonge CS. The Magnitude and Determinants of Missed Opportunities for Childhood
421 Vaccination in South Africa. Vaccines (Basel). 2020;8(4).

422 **Supporting information:**

423 **S1 Table: Vaccination coverage amongst all children under one year who have completed their primary course**
424 **of immunisation in South Africa**

425 **S2 Table: Distribution of HBsAg positive cases by province and age group stratified by gender**

426 **S3 Table: Distribution of HBV chronic cases by province and age group stratified by gender**




*Deduplication deletes duplicate cases with multiple HBsAg results, maintaining the first and deleting all subsequent records.

**Merging of duplicates merges selected variables of multiple records into a single record.


***Represents the number of chronic HBV cases within this group.

Figure 1: HBsAg sample number breakdown from the appended dataset of records from 2015 to 2019; from the dataset of valid HBsAg results to the master HBsAg dataset (a), from the master HBsAg dataset to a breakdown of Group_M (b), and from the master HBsAg dataset to a breakdown of Group_C (c)



medRxiv preprint doi: <https://doi.org/10.1101/2022.08.09.22278594>; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 2: National distribution of HBsAg positive cases 2015 to 2019 (n = 176,530); province by gender (a) age group by gender (b), and province distribution versus 100,000 province population (c)



medRxiv preprint doi: <https://doi.org/10.1101/2022.08.09.22278594>; this version posted August 10, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 3: National distribution of HBV chronic cases 2015 to 2019 (n = 11,355); province by gender (a), age group by gender (b), and province distribution versus 100,000 province population (c)